SG11201909932YA - Pharmaceutical agents, compositions, and methods relating thereto - Google Patents
Pharmaceutical agents, compositions, and methods relating theretoInfo
- Publication number
- SG11201909932YA SG11201909932YA SG11201909932YA SG11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA SG 11201909932Y A SG11201909932Y A SG 11201909932YA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- nicholasville
- catnip
- hill road
- methods
- Prior art date
Links
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 241001529733 Nepeta Species 0.000 abstract 5
- 235000010679 Nepeta cataria Nutrition 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- ZDKZHVNKFOXMND-UHFFFAOYSA-N epinepetalactone Chemical compound O=C1OC=C(C)C2C1C(C)CC2 ZDKZHVNKFOXMND-UHFFFAOYSA-N 0.000 abstract 5
- 239000000203 mixture Substances 0.000 abstract 3
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229930024421 Adenine Natural products 0.000 abstract 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 abstract 1
- 241000995051 Brenda Species 0.000 abstract 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 229960000643 adenine Drugs 0.000 abstract 1
- 229960005305 adenosine Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 239000011593 sulfur Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/167—Purine radicals with ribosyl as the saccharide radical
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762508730P | 2017-05-19 | 2017-05-19 | |
| PCT/US2018/030371 WO2018212980A1 (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201909932YA true SG11201909932YA (en) | 2019-11-28 |
Family
ID=64274560
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201909932Y SG11201909932YA (en) | 2017-05-19 | 2018-05-01 | Pharmaceutical agents, compositions, and methods relating thereto |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11014954B2 (enExample) |
| EP (1) | EP3624809A4 (enExample) |
| JP (1) | JP7224303B2 (enExample) |
| CN (2) | CN120647702A (enExample) |
| AU (1) | AU2018269403B2 (enExample) |
| CA (1) | CA3061893A1 (enExample) |
| NZ (1) | NZ758538A (enExample) |
| RU (1) | RU2765286C2 (enExample) |
| SA (1) | SA519410561B1 (enExample) |
| SG (1) | SG11201909932YA (enExample) |
| WO (1) | WO2018212980A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002305073A1 (en) * | 2001-03-22 | 2002-10-08 | Research Foundation Of The City University Of New York | Synthesis of selenium-derivatized nucleosides, nucleotides, phosphoramidites, triphosphates and nucleic acids |
| US20030078232A1 (en) | 2001-08-08 | 2003-04-24 | Elfatih Elzein | Adenosine receptor A3 agonists |
| EP1652519A1 (en) | 2004-10-28 | 2006-05-03 | Tamie Nasu | Seleniferous composition for producing antioxidase in vivo |
| US20060198906A1 (en) | 2005-03-07 | 2006-09-07 | Sami Labs Limited | Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease |
| US20070077238A1 (en) | 2005-10-04 | 2007-04-05 | Teo Alex Y | Production of organic and inorganic selenium compounds by lactic acid bacteria |
| ATE497960T1 (de) * | 2005-10-13 | 2011-02-15 | Cv Therapeutics Inc | A1-adenosinrezeptoragonisten |
| WO2009032057A2 (en) | 2007-08-29 | 2009-03-12 | Adam Lubin | Method for the selective therapy of disease |
| WO2013151975A1 (en) | 2012-04-02 | 2013-10-10 | Northeastern University | Compositions and methods for the inhibition of methyltransferases |
| RU2663127C2 (ru) | 2013-03-15 | 2018-08-01 | Олтек, Инк. | Селенсодержащие композиции и их применение для лечения и предотвращения заболеваний или состояний, связанных с митохондриальной дисфункцией |
| CA2940283C (en) * | 2014-03-14 | 2021-03-30 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| US20160090397A1 (en) | 2014-09-30 | 2016-03-31 | Northeastern University | Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities |
| WO2017048252A1 (en) * | 2015-09-15 | 2017-03-23 | Alltech, Inc. | Compositions of selenoorganic compounds and methods of use thereof |
| CN120647702A (zh) | 2017-05-19 | 2025-09-16 | 全技术公司 | 药剂、组合物及其相关方法 |
-
2018
- 2018-05-01 CN CN202510741418.6A patent/CN120647702A/zh active Pending
- 2018-05-01 RU RU2019134865A patent/RU2765286C2/ru active
- 2018-05-01 CN CN201880027339.7A patent/CN110545822A/zh active Pending
- 2018-05-01 NZ NZ758538A patent/NZ758538A/en active IP Right Revival
- 2018-05-01 SG SG11201909932Y patent/SG11201909932YA/en unknown
- 2018-05-01 AU AU2018269403A patent/AU2018269403B2/en active Active
- 2018-05-01 US US16/490,836 patent/US11014954B2/en active Active
- 2018-05-01 EP EP18801931.9A patent/EP3624809A4/en active Pending
- 2018-05-01 WO PCT/US2018/030371 patent/WO2018212980A1/en not_active Ceased
- 2018-05-01 JP JP2019563067A patent/JP7224303B2/ja active Active
- 2018-05-01 CA CA3061893A patent/CA3061893A1/en active Pending
-
2019
- 2019-11-14 SA SA519410561A patent/SA519410561B1/ar unknown
-
2021
- 2021-04-23 US US17/238,354 patent/US11613552B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA3061893A1 (en) | 2018-11-22 |
| CN120647702A (zh) | 2025-09-16 |
| NZ758538A (en) | 2025-08-29 |
| CN110545822A (zh) | 2019-12-06 |
| AU2018269403B2 (en) | 2025-03-27 |
| JP7224303B2 (ja) | 2023-02-17 |
| AU2018269403A1 (en) | 2019-11-14 |
| SA519410561B1 (ar) | 2024-03-06 |
| RU2019134865A3 (enExample) | 2021-06-30 |
| WO2018212980A1 (en) | 2018-11-22 |
| US20200123191A1 (en) | 2020-04-23 |
| US11014954B2 (en) | 2021-05-25 |
| US11613552B2 (en) | 2023-03-28 |
| RU2765286C2 (ru) | 2022-01-28 |
| US20210238216A1 (en) | 2021-08-05 |
| JP2020520904A (ja) | 2020-07-16 |
| EP3624809A1 (en) | 2020-03-25 |
| EP3624809A4 (en) | 2021-03-03 |
| RU2019134865A (ru) | 2021-06-21 |
| BR112019022918A2 (pt) | 2020-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201907650RA (en) | Personal therapy and exercise monitoring and oversight devices, systems, and related methods | |
| SG11201804901WA (en) | Compounds for the treatment of cancer and inflammatory disease | |
| SG11201908567UA (en) | Modified cyclic dinucleotide compounds | |
| SG11201908719QA (en) | Biomarkers and car t cell therapies with enhanced efficacy | |
| SG11201900480YA (en) | Anti-tim-3 antibodies | |
| SG11201806624XA (en) | Deposition of molybdenum thin films using a molybdenum carbonyl precursor | |
| SG11201809669RA (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| SG11201900633XA (en) | Piperidine cxcr7 receptor modulators | |
| SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
| SG11201907561PA (en) | Anti-lag-3 antibodies and uses thereof | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201806583XA (en) | Compositions containing tucaresol or its analogs | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201907023UA (en) | Method of reducing neutropenia | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201901558VA (en) | Pth compounds with low peak-to-trough ratios | |
| SG11201907693VA (en) | Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201908472VA (en) | Compositions and methods for activating nk cells | |
| SG11201908490TA (en) | Compositions and methods and uses relating thereto |